EHA 2017 | Developing safe and effective agents for the treatment of CLL

Paolo Ghia

Paolo Ghia, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about the current goals in chronic lymphocytic leukemia (CLL) therapy, particularly in the development of effective and safe novel agents that may provide good clinical benefit for a time-limited period, and the issues associated with these goals. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

Share this video  
Similar topics